Floatz logo

Mirvetuximab Soravtansine

Recurrent Uterine Carcinosarcoma

Ohio State University Comprehensive Cancer Centerantibody_drug_conjugatePhase 1Dormant
CC
47/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
32/ 100
Competitive Position
95/ 100

Competitive context

7 Active assets in the Recurrent Uterine Carcinosarcoma cohort.

Asset / SponsorPhaseRating
Carboplatin
GOG Foundation
Phase 3B
Ifosfamide
GOG Foundation
Phase 3B
Temsirolimus
National Cancer Institute (NCI)
Phase 2B
Sorafenib
National Cancer Institute (NCI)
Phase 2B
Niraparib
ARCAGY/ GINECO GROUP
Phase 2/3B

View all 14 →

Same molecule, other indications

Mirvetuximab Soravtansine is also rated in:

ovarian carcinomaDormant
BBB
Indicative ·
76 / 100
View asset →
fallopian tube cancerDormant
BB
Indicative ·
70 / 100
View asset →
primary peritoneal carcinomaDormant
BB
Indicative ·
70 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →